Long-term acid suppression increases bacterial overgrowth, Clostridioides difficile and other enteric infections, and changes the gut microbiome.

Original statement

حمض المعدة ليس عدوّاً يجب قمعه، بل أداة أساسية للهضم وقتل الميكروبات وامتصاص الحديد وفيتامين ب12 والكالسيوم والمغنيزيوم. تثبيطه لفترات طويلة بـ PPIs (أوميبرازول، نكسيم، كونترلوك) أو مثبطات H2 ينقلب على الجسم: مرض كلوي مزمن، فرط نمو بكتيري، عدوى مطثية عسيرة، التهاب رئوي، نقص B12 والمغنيزيوم، كسور ورك، تغيّر الميكروبيوم، وزيادة الوفيات. والأخطر أنّ الجسم يدمن الدواء عبر فرط الإفراز الارتدادي بعد الإيقاف، فيتحوّل الاستخدام القصير إلى اعتماد مزمن.

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

Long-term acid suppression increases bacterial overgrowth, Clostridioides difficile and other enteric infections, and changes the gut microbiome.

Origin

Source status

Archive editors

Attribution

Archive editors (eltayebat.com); not verified as Elawady's own words

Origin

https://eltayebat.com/rule/acid-blockers/

Attribution uncertainty

Written by the archive operators; study selection is the archive's, not necessarily Elawady's.

Claimed mechanism

Removal of the gastric acid barrier allows oral and upper-GI bacteria to reach and colonise the lower gut.

Claimed health effect

C. difficile infection, enteric infections, SIBO, reduced microbiome diversity.

Population concerned

PPI users.

Geographic restriction by Elawady

none found

Diverging source versions

Scientific assessment

Mostly true – Correct at its core, but with limitations or minor inaccuracies.

Certainty of evidence: moderate – Further research may still affect the assessment.

1. What was claimed?

Acid blockers favour bacterial overgrowth and gut infections and alter the microbiome.

2. What is demonstrably correct?

This is largely correct. The COMPASS RCT found more enteric infections with pantoprazole (1.4% vs 1.0%; OR 1.33, 95% CI 1.01–1.75); meta-analyses report pooled ORs of about 1.7–2.0 for C. difficile; twin and population cohorts show lower diversity and more oral bacteria in the stool of PPI users.

3. What is wrong or exaggerated?

The size of the C. difficile effect is uncertain (high heterogeneity, publication bias). SIBO was associated with PPI use only when diagnosed by aspirate culture, not by breath test. 'Microbiome change' is not the same as proven disease.

4. What remains unclear?

Long-term clinical consequences of the microbiome shifts beyond infection are not established.

5. Which studies support it?

A-PPI-05, A-PPI-06, A-PPI-15, A-PPI-16, A-PPI-17; COMPASS (I-PPI-01) for enteric infections.

6. Which studies contradict it?

COMPASS: C. difficile was about twice as common with pantoprazole but with only 13 events and no statistical significance.

7. What applies to Germany and Europe?

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

8. What is known about Egypt?

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

9. What practical conclusion is appropriate?

This is a valid reason to avoid PPIs without a clear indication, especially in hospitalised or antibiotic-treated people, but not a reason to refuse an indicated PPI.

Assessment details

Rationale for certainty of evidence

Many observational studies and meta-analyses show about 1.7–2-fold odds of C. difficile; microbiome studies consistently show compositional changes; the COMPASS RCT confirmed more enteric infections (OR 1.33) with pantoprazole. Heterogeneity and publication bias in the meta-analyses lower certainty for the exact size.

Source quality

Supported by meta-analyses, large microbiome cohorts and one large RCT.

Regional transferability

High; findings come from North America, Europe and Asia.

Individual exceptions

Absolute risk is low for most users; risk is higher in hospitalised, older and antibiotic-treated people.

Regional scope of the claim

general (biological/medical)

Last reviewed

26 October 2026 provisional

Scientific evidence in detail

Scientifically well supported – The claim agrees with consistent, high-quality evidence.

Research question: Does long-term acid suppression increase bacterial overgrowth, C. difficile and other enteric infections and change the gut microbiome?

Study results as reported by the authors. Our assessment follows below.

Open questions

C. difficile risk in long-term outpatient use.

How deeply was this checked?

8 linked studies: 1 checked in full text (1 of them with a structured risk-of-bias assessment), 7 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

In plain language

Stomach acid kills many bacteria that we swallow. When acid is strongly reduced for a long time, more of these bacteria reach the intestine. Studies show a somewhat higher risk of gut infections, including C. difficile, in people who take PPIs, and a randomised trial confirmed a small increase in gut infections. For most people the absolute risk stays low.

Studies on this claim

Regional context

Germany / EU

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

Egypt

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

What applies in my country?

General scientific assessment

Mostly true Correct in substance: PPIs modestly raise the risk of gut infections and alter gut bacteria.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

1. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis.. Trifan A et al.. World J Gastroenterol 2017 · PMID 29085200 · DOI 10.3748/wjg.v23.i35.6500
2. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis.. Janarthanan S et al.. Am J Gastroenterol 2012 · PMID 22710578 · DOI 10.1038/ajg.2012.179
3. Proton pump inhibitors alter the composition of the gut microbiota.. Jackson MA et al.. Gut 2016 · PMID 26719299 · DOI 10.1136/gutjnl-2015-310861
4. Proton pump inhibitors affect the gut microbiome.. Imhann F et al.. Gut 2016 · PMID 26657899 · DOI 10.1136/gutjnl-2015-310376
5. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis.. Lo WK et al.. Clin Gastroenterol Hepatol 2013 · PMID 23270866 · DOI 10.1016/j.cgh.2012.12.011
6. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.. Moayyedi P et al.. Gastroenterology 2019 · PMID 31152740 · DOI 10.1053/j.gastro.2019.05.056
7. Proton Pump Inhibitor Use for Gastroprotection and Stress Ulcer Prophylaxis Does Not Increase the Risk of Clostridioides difficile Infection or Pneumonia: A Systematic Review and Meta-Analysis of RCTs.. Omar MA et al.. J Clin Med 2026 · PMID 41976918 · DOI 10.3390/jcm15072617
8. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.. Freedberg DE et al.. Gastroenterology 2017 · PMID 28257716 · DOI 10.1053/j.gastro.2017.01.031